{
    "nctId": "NCT01658956",
    "briefTitle": "Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia",
    "officialTitle": "A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 142,
    "primaryOutcomeMeasure": "Occurrence of a febrile neutropenic episode defined as fever (>=38.5\u00b0C once or >=38\u00b0C twice within 12 hours interval) and neutropenia (ANC < 0.5 IU)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nBreast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC, docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant\n\nExclusion Criteria:\n\nEligibility to receive reimbursed GCSF",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}